Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Alisertib + Rituximab + Vincristine Sulfate|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alisertib||MLN8237||Aurka Inhibitors 23||Alisertib (MLN8237) binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation (PMID: 26999067, PMID: 32414750).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 7||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Vincristine Sulfate||Oncovin||22-Oxovincaleukoblastine||Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||B-cell lymphoma||not applicable||Alisertib + Rituximab + Vincristine Sulfate||Phase I||Actionable||In a Phase I trial, Alisertib (MLN8237) in combination with Rituxan (rituximab) and Oncovin (vincristine) demonstrated safety and efficacy, resulted in an objective response rate of 38% (14/37, 7 complete response, 7 partial response), and stable disease in 32% (12/37) of patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PMID: 30082475; NCT01397825).||30082475|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|